Searched for
CONCORD BIOTECH IPO
Concord Biotech's niche strengths seen buoying earnings: AnalystsShares of the Ahmedabad-based biopharma company, which listed a few weeks ago at a more than 20% premium, have notched another 9% gain sinc...- September likely to witness a flood of locked-in sharesEnding of the lock-in period does not necessarily mean investors who received shares in the pre-IPO sale will offload their entire holdings...
- US a key market, have strong presence in it: Ankur Vaid, Concord BiotechSo we expect to do better than what we have done historically, which was a CAGR growth of 18%. And this as economies of scale would kick in...
- Concord Biotech shares list at a healthy premium. What should investors do?Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in ...
- Concord Biotech shares list at 21% premium over IPO priceConcord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in ...
- Concord Biotech to list on Friday. Here’s what GMP suggestsAnalysts are of the opinion that a market premium of over 15% on the issue price is justified based on the company's business model, which ...
- Concord Biotech IPO share allotment likely today. Here's how you can check statusOn the allotment date, investors get to know about the number of shares allotted to them as against the bids made. They can check the allot...
- Concord Biotech IPO: Issue subscribed 25 times on last day; check GMP and other detailsAnalysts advised investors to subscribe to the issue given its complex product portfolio, presence in niche space, strong client relationsh...
- Concord Biotech IPO fully subscribed on Day 2. Retail portion booked 2.26 timesThe total number of shares available for subscription stood at 14,650,957, and the share bids received around this time stood at 17,847,340...
- SBFC Finance vs Concord Biotech: Which IPO should you pick?The issue of SBFC Finance comprises fresh equity issue of Rs 600 crore and an offer for sale (OFS) of Rs 425 crore, while Concord Biotech i...
- Concord Biotech IPO subscribed 58% on Day OneThe non-institutional investors (NII) category was subscribed the most at 1.01 times, followed by retail investors at 72%. The category for...
- Concord Biotech IPO opens. Should you subscribe to the issue?Analysts advised investors to subscribe to Concord Biotech IPO given its complex product portfolio, presence in niche space, strong client ...
- Concord Biotech IPO: GMP indicates strong investors' interest ahead of issue openingAhead of the issue opening, the company's shares commanded a premium of Rs Rs 325 in the unlisted market
- Concord Biotech IPO to open on August 4. Here are 10 things to know about the offerThe initial public offering (IPO) of Concord Biotech will open for subscription on August 4. The issue closes on August 8. The company's sh...
- Concord Bio's Rs 1,551-crore IPO to open on Aug 4The issue, which will close on August 8, is entirely an offer-for-sale, where the existing shareholder Helix Investments Holdings will sell...
- Jhunjhunwala-backed Concord Biotech sets IPO price band at Rs 705-741According to the draft papers, Concord Biotech's IPO is entirely an offer for sale of (OFS) of 2,09,25,652 equity shares by Helix Investmen...
- Concord Biotech, Vaibhav Gems get Sebi's approval to float IPOsThe company is backed by Quadria Capital Fund and Rare Enterprises, which was set up by billionaire investor Rakesh Jhunjhunwala, along wit...
- Three companies file papers to raise Rs 7,500 cr as buzz returns to IPO marketSo far in 2022, about 63 companies have filed draft papers with Sebi, while 17 companies, including LIC, have raised about ₹41,140 crore fr...
- Concord Biotech files DRHP with Sebi for Rs 2,000-2,500 cr IPOSources told ET that the IPO would be of ₹2000 crore - ₹2500 crore size.The issue with a face value of ₹1 per equity share is a complete of...
- Rare Enterprises, Quadria-backed Concord Biotech files draft IPO papers with SebiAs per an F&S report, Concord Biotech commands a market share of over 20 per cent by volume in 2021 across identified fermentation-based AP...
Load More
